ReviewAnnals of translational medicine2016
Migraine in the era of precision medicine.
Review in Annals of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05646160 (Effects of Myofascial Trigger Points Therapy in Migraine.), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Myofascial Trigger Points Therapy in Migraine.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients - pilot study.BMC musculoskeletal disorders · 2025Trial
- The emerging role of epigenetic regulation in pain sensitization associated with headache disorders.The journal of headache and pain · 2025Review
- Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment.Pain management · 2025Review
- Intelligent Digital Twins for Personalized Migraine Care.Journal of personalized medicine · 2023Review
- Is There an Association Between Migraine and Major Depressive Disorder? A Narrative Review.Cureus · 2020Review
- Current Evidence on Potential Uses of MicroRNA Biomarkers for Migraine: From Diagnosis to Treatment.Molecular diagnosis & therapy · 2019Review
- Predicting treatment response using pharmacy register in migraine.The journal of headache and pain · 2019Article
- The Revolution in Migraine Genetics: From Aching Channels Disorders to a Next-Generation Medicine.Frontiers in cellular neuroscience · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a common neurovascular disorder in the neurologic clinics whose mechanisms have been explored for several years. The aura has been considered to be attributed to cortical spreading depression (CSD) and dysfunction of the trigeminovascular system is the key factor that has been considered in the pathogenesis of migraine pain. Moreover, three genes (CACNA1A, ATP1A2, and SCN1A) have come from studies performed in individuals with familial hemiplegic migraine (FHM), a monogenic form of migraine with aura. Therapies targeting on the neuropeptids and genes may be helpful in the precision medicine of migraineurs. 5-hydroxytryptamine (5-HT) receptor agonists and calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated efficacy in the acute specific treatment of migraine attacks. Therefore, ongoing and future efforts to find new vulnerabilities of migraine, unravel the complexity of drug therapy, and perform biomarker-driven clinical trials are necessary to improve outcomes for patients with migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.